MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

United Therapeutics Corp

Abierto

SectorSanidad

290.26 -1.53

Resumen

Variación precio

24h

Actual

Mínimo

286.55

Máximo

297.62

Métricas clave

By Trading Economics

Ingresos

-7.8M

301M

Ventas

-13M

736M

P/B

Media del Sector

11.884

57.333

BPA

6.19

Margen de beneficios

40.943

Empleados

1,305

EBITDA

6.3M

424M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+29.27% upside

Dividendos

By Dow Jones

Próximas Ganancias

30 abr 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-3.4B

13B

Apertura anterior

291.79

Cierre anterior

290.26

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

United Therapeutics Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

7 oct 2024, 15:14 UTC

Principales Movimientos del Mercado

Liquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal

28 ene 2025, 10:30 UTC

Principales Noticias

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

Comparación entre iguales

Cambio de precio

United Therapeutics Corp previsión

Precio Objetivo

By TipRanks

29.27% repunte

Estimación a 12 Meses

Media 383.18 USD  29.27%

Máximo 460 USD

Mínimo 293 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para United Therapeutics Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

11 ratings

8

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

285.09 / 298.295Soporte y Resistencia

Corto Plazo

Very Strong Bullish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.